David Mauro
Overview
Explore the profile of David Mauro including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
866
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Neoadjuvant vidutolimod and nivolumab in high-risk resectable melanoma: A prospective phase II trial
Davar D, Morrison R, Dzutsev A, Karunamurthy A, Chauvin J, Amatore F, et al.
Cancer Cell
. 2024 Nov;
42(11):1898-1918.e12.
PMID: 39486411
Intratumoral TLR9 agonists and anti-PD-1 produce clinical responses and broad immune activation. We conducted a single-arm study of neoadjuvant TLR9 agonist vidutolimod combined with anti-PD-1 nivolumab in high-risk resectable melanoma....
2.
Margalit O, Lieberman S, Redinsky I, Halparin S, Honig N, Raskin S, et al.
Clin Colorectal Cancer
. 2023 Sep;
22(4):442-449.e1.
PMID: 37657954
Introduction: Microsatellite stable metastatic colorectal cancer (MSS mCRC) is largely refractory to immune checkpoint inhibition. We hypothesized that a combination of intratumoral TLR9 agonist, radiosurgery and dual PD-1 and CTLA-4...
3.
Negrao M, Papadimitrakopoulou V, Price A, Tam A, Furqan M, Laroia S, et al.
JTO Clin Res Rep
. 2023 Mar;
4(3):100423.
PMID: 36925644
Introduction: Vidutolimod, a CpG-A TLR9 agonist, was investigated in a phase 1b study (CMP-001-003; ClinicalTrials.gov, NCT03438318) in combination with atezolizumab with and without radiation therapy (RT) in patients with advanced...
4.
Rogers T, Shah N, Mauro D, McGinty K
Radiol Case Rep
. 2022 Oct;
17(12):4889-4892.
PMID: 36276658
The liver is a rare site for anastomosing hemangiomas with only a few cases reported that characterize the lesions on magnetic resonance imaging (MRI). These lesions may be underreported due...
5.
Ribas A, Medina T, Kirkwood J, Zakharia Y, Gonzalez R, Davar D, et al.
Cancer Discov
. 2021 Jul;
11(12):2998-3007.
PMID: 34326162
Significance: In this phase Ib study in patients with advanced melanoma, intratumoral TLR9 agonist vidutolimod in combination with pembrolizumab had a manageable safety profile and showed promising clinical activity, supporting...
6.
Yacoub J, Mauro D, Moon A, He A, Bashir M, Hsu C, et al.
Abdom Radiol (NY)
. 2021 Apr;
46(8):3540-3548.
PMID: 33864107
Locoregional therapies can be offered to hepatocellular carcinoma patients as a bridge to transplant, to downstage disease burden for transplant eligibility, or for disease control to prolong survival. Systemic therapies...
7.
Yacoub J, Hsu C, Fishbein T, Mauro D, Moon A, He A, et al.
Abdom Radiol (NY)
. 2021 Apr;
46(8):3528-3539.
PMID: 33835223
Hepatocellular carcinoma (HCC) offers unique management challenges as it commonly occurs in the setting of underlying chronic liver disease. The management of HCC is directed primarily by the clinical stage....
8.
Walburn T, Moon A, Hayashi P, Gerber D, Sanoff H, McGinty K, et al.
Cureus
. 2020 Sep;
12(8):e9988.
PMID: 32983688
Lymph node metastases from hepatocellular carcinoma (HCC) represents a challenging clinical scenario with a poor prognosis, especially in the setting of prior liver transplant. Long-term survival is achievable in select...
9.
Aurisicchio L, Fridman A, Mauro D, Sheloditna R, Chiappori A, Bagchi A, et al.
J Transl Med
. 2020 Feb;
18(1):39.
PMID: 32000810
Background: Human telomerase reverse transcriptase (hTERT) is an antigen that may represent a target for a novel anti-cancer strategy. A pilot, phase I study tested the safety and feasibility of...
10.
Baselga J, Morales S, Awada A, Blum J, Tan A, Ewertz M, et al.
Breast Cancer Res Treat
. 2017 Mar;
163(3):535-544.
PMID: 28324268
Purpose: Combining the mTOR inhibitor ridaforolimus and the anti-IGFR antibody dalotuzumab demonstrated antitumor activity, including partial responses, in estrogen receptor (ER)-positive advanced breast cancer, especially in high proliferation tumors (Ki67 ...